A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor|Head and Neck Squamous Cell Carcinoma|Bladder Carcinoma|Susceptible FGFR3 Genetic Alterations|FGFR3|FGFR3 Overexpression|FGFR3 Receptor|FGFR3 Protein Overexpression|Ovarian Cancer|Colorectal Cancer|Breast Cancer|Liver Cancer|Lung Cancer|Gastric Cancer
Interventions: DRUG: [225Ac]-FPI-1966|DRUG: [111In]-FPI-1967|BIOLOGICAL: vofatamab
Sponsor: Fusion Pharmaceuticals Inc.